422 related articles for article (PubMed ID: 25154420)
1. Prostate-specific antigen (PSA) screening and follow-up investigations in Māori and non-Māori men in New Zealand.
Obertová Z; Scott N; Brown C; Hodgson F; Stewart A; Holmes M; Lawrenson R
BMC Fam Pract; 2014 Aug; 15():145. PubMed ID: 25154420
[TBL] [Abstract][Full Text] [Related]
2. Ethnic and socio-economic disparities in prostate cancer screening: lessons from New Zealand.
Matti B; Lyndon M; Zargar-Shoshtari K
BJU Int; 2021 Dec; 128 Suppl 3():11-17. PubMed ID: 32599662
[TBL] [Abstract][Full Text] [Related]
3. Do Maori and Pacific Islander men present with more advanced prostate cancer than European New Zealand men? An analysis of 486 men undergoing biopsy in Auckland.
Pokorny MR; Scott DJ
BJU Int; 2011 Apr; 107 Suppl 3():27-32. PubMed ID: 21492373
[TBL] [Abstract][Full Text] [Related]
4. Rural-Urban Differences in Prostate-Specific Antigen (PSA) Screening and Its Outcomes in New Zealand.
Obertová Z; Hodgson F; Scott-Jones J; Brown C; Lawrenson R
J Rural Health; 2016; 32(1):56-62. PubMed ID: 26174590
[TBL] [Abstract][Full Text] [Related]
5. Inequalities between Māori and non-Māori men with prostate cancer in Aotearoa New Zealand.
Egan R; Lawrenson R; Kidd J; Cassim S; Black S; Blundell R; Bateman J; Broughton JR
N Z Med J; 2020 Sep; 133(1521):69-76. PubMed ID: 32994638
[TBL] [Abstract][Full Text] [Related]
6. Elevated serum prostate-specific antigen levels and public health implications in three New Zealand ethnic groups: European, Maori, and Pacific Island men.
Gray M; Borman B; Crampton P; Weinstein P; Wright C; Nacey J
N Z Med J; 2005 Feb; 118(1209):U1295. PubMed ID: 15711628
[TBL] [Abstract][Full Text] [Related]
7. Treatment modalities for Māori and New Zealand European men with localised prostate cancer.
Obertová Z; Lawrenson R; Scott N; Holmes M; Brown C; Lao C; Tyrie L; Gilling P
Int J Clin Oncol; 2015 Aug; 20(4):814-20. PubMed ID: 25557325
[TBL] [Abstract][Full Text] [Related]
8. Prostate cancer screening practices in a large, integrated health system: 2007-2014.
Misra-Hebert AD; Hu B; Klein EA; Stephenson A; Taksler GB; Kattan MW; Rothberg MB
BJU Int; 2017 Aug; 120(2):257-264. PubMed ID: 28139034
[TBL] [Abstract][Full Text] [Related]
9. Survival disparities between Māori and non-Māori men with prostate cancer in New Zealand.
Obertová Z; Scott N; Brown C; Stewart A; Lawrenson R
BJU Int; 2015 Apr; 115 Suppl 5():24-30. PubMed ID: 25124231
[TBL] [Abstract][Full Text] [Related]
10. Improving survival disparities in cervical cancer between Māori and non-Māori women in New Zealand: a national retrospective cohort study.
McLeod M; Harris R; Purdie G; Cormack D; Robson B; Sykes P; Crengle S; Iupati D; Walker N
Aust N Z J Public Health; 2010 Apr; 34(2):193-9. PubMed ID: 23331365
[TBL] [Abstract][Full Text] [Related]
11. PSA screening, prostate biopsy, and treatment of prostate cancer in the years surrounding the USPSTF recommendation against prostate cancer screening.
Kearns JT; Holt SK; Wright JL; Lin DW; Lange PH; Gore JL
Cancer; 2018 Jul; 124(13):2733-2739. PubMed ID: 29781117
[TBL] [Abstract][Full Text] [Related]
12. The effect of Māori ethnicity misclassification on cervical screening coverage.
Sandiford P; Salvetto M; Bramley D; Wong S; Johnson L
N Z Med J; 2013 Apr; 126(1372):55-65. PubMed ID: 23793178
[TBL] [Abstract][Full Text] [Related]
13. Variation in general practice prostate-specific antigen testing and prostate cancer outcomes: an ecological study.
Hjertholm P; Fenger-Grøn M; Vestergaard M; Christensen MB; Borre M; Møller H; Vedsted P
Int J Cancer; 2015 Jan; 136(2):435-42. PubMed ID: 24905402
[TBL] [Abstract][Full Text] [Related]
14. Opportunistic testing versus organized prostate-specific antigen screening: outcome after 18 years in the Göteborg randomized population-based prostate cancer screening trial.
Arnsrud Godtman R; Holmberg E; Lilja H; Stranne J; Hugosson J
Eur Urol; 2015 Sep; 68(3):354-60. PubMed ID: 25556937
[TBL] [Abstract][Full Text] [Related]
15. The patient perspective on a first raised PSA test.
Brown C; Hodgson F; Obertova Z; Holmes M; Lawrenson R
J Prim Health Care; 2015 Sep; 7(3):213-20. PubMed ID: 26437045
[TBL] [Abstract][Full Text] [Related]
16. Screening for prostate cancer in New Zealand general practice.
Zuzana O; Ross L; Fraser H; Charis B; Alistair S; Leanne T; Michael H; Peter G
J Med Screen; 2013 Mar; 20(1):49-51. PubMed ID: 23612467
[TBL] [Abstract][Full Text] [Related]
17. Do racial disparities exist in the use of prostate cancer screening and detection tools in veterans?
Hudson MA; Luo S; Chrusciel T; Yan Y; Grubb RL; Carson K; Scherrer JF
Urol Oncol; 2014 Jan; 32(1):34.e9-18. PubMed ID: 23506962
[TBL] [Abstract][Full Text] [Related]
18. The costs of identifying undiagnosed prostate cancer in asymptomatic men in New Zealand general practice.
Lao C; Brown C; Obertová Z; Edlin R; Rouse P; Hodgson F; Holmes M; Gilling P; Lawrenson R
Fam Pract; 2013 Dec; 30(6):641-7. PubMed ID: 24055993
[TBL] [Abstract][Full Text] [Related]
19. Ethnic differences in acute hospitalisations for otitis media and elective hospitalisations for ventilation tubes in New Zealand children aged 0-14 years.
McCallum J; Craig L; Whittaker I; Baxter J
N Z Med J; 2015 Jun; 128(1416):10-20. PubMed ID: 26117671
[TBL] [Abstract][Full Text] [Related]
20. Access to Prostate-Specific Antigen Testing and Mortality Among Men With Prostate Cancer.
Iyer HS; Stone BV; Roscoe C; Hsieh MC; Stroup AM; Wiggins CL; Schumacher FR; Gomez SL; Rebbeck TR; Trinh QD
JAMA Netw Open; 2024 Jun; 7(6):e2414582. PubMed ID: 38833252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
